ReviewIbrain2026
Roles of histone lysine methylation in neurodevelopment and related disorders.
Review in Ibrain, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurodevelopment is a highly ordered, precisely regulated process that establishes the neurobiological foundations of cognition, thought, emotion, and behavior. Neurodevelopmental disorders (NDDs) display marked phenotypic and genetic heterogeneity and variably impair learning, daily functioning, and social adaptation. As a key epigenetic mechanism, histone lysine methylation shapes chromatin accessibility and transcriptional programs, exerting central roles in neural stem cell fate decisions, neuronal migration and circuit assembly, as well as synaptic plasticity and learning and memory. Focusing on the activating histone H3 lysine 4 (H3K4) methylation marks (H3K4me1/2/3), this review synthesizes evidence for the bidirectional regulation mediated by "writers" (the KMT2/SET/DOT1) and "erasers" (the KDM/LSD and KDM5) in NDDs, including Kabuki syndrome, Wiedemann-Steiner syndrome, autism spectrum disorder, and schizophrenia. We further outline how animal models, patient-derived brain organoids, and multi-omics atlases enhance mechanistic insight, and we discuss the translational potential of small-molecule interventions, and metabolic modulation. Together, we summarize how the precise balance of methylation writing and erasure-and its crosstalk with DNA methylation and histone acetylation-forms an epigenetic network that drives neurodevelopmental programs. Targeting this network offers testable therapeutic avenues for NDDs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.